In article

In a press release dated 26 August 2017, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the US Food and Drug Administration has granted ‘Breakthrough Therapy’ designation¬†for MDMA-assisted psychotherapy for PTSD.

The FDA grants Breakthrough Therapy designation to treatments that preliminary clinical evidence indicates may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

Read the full press release here.



Recommended Posts
Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search